Chong Kun Dang exports biosimilar referencing anemia treatment to Japanese branch

Chong Kun Dang(CEO Young-Joo Kim) recently signed a business partnership agreement of ‘CKD-11101,’ a second-generation anemia treatment biosimilar, with a U.S. global pharmaceutical company’s Japanese branch. The agreement includes exportation of its finished drugs as well.

Under the agreement, the Japanese branch will carry out getting approval for its clinical trials in Japan and will exclus...